Secukinumab Provides Complete or Almost-Complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials

A Blauvelt; A Armstrong; P Rich; R Kisa; A Guana; X Meng; K Callis Duffin

doi:10.25251/skin.2.supp.19

A Blauvelt
A Armstrong
P Rich
R Kisa
A Guana
X Meng
K Callis Duffin

Keywords

psoriasis, secukinumab, clinical trial

Abstract

Abstract not available.

Disclosures: Study sponsored by Novartis.

Poster PDF

Published

Feb 23, 2018

DOI https://doi.org/10.25251/skin.2.supp.19

How to Cite

Blauvelt, A., Armstrong, A., Rich, P., Kisa, R., Guana, A., Meng, X., & Callis Duffin, K. (2018). Secukinumab Provides Complete or Almost-Complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials. SKIN The Journal of Cutaneous Medicine, 2(S1), S19. https://doi.org/10.25251/skin.2.supp.19

Issue

Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

G Martin, B Berman, S Feldman, A Armstrong , M Edwards, S Graziadio, R McCool, M Arber, E Carr, D James, M Chapman-Rounds, E Fumero, M Schuchardt, A Grada, Field Treatments for Actinic Keratosis: A Systematic Review and Network Meta-Analysis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
A Moore, L Green, S Bruce, N Sadick, E Tschen, P Werschler, S Dhawan, D Forsha, M Gold, S Guenthner, S Kempers, L Kircik, J Parish, M Rendon, P Rich, L Stein-Gold, S Tyring, R Weiss, A Nasir, C Schmitz, T Boodhoo, A Kaoukhov, D Berk, F Cook-Bolden, Ayman Grada, Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-blind Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
D Thaçi, A Armstrong, M Lebwohl, A Blauvelt, C Paul, L Puig, M Wang, V Vanvoorden, C Madden, S Wiegratz, D Deherder, KB Gordon, Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
A Gottlieb, M Lebwohl, A Armstrong, RJ Israel, A Jacobson, Malignancy Events in Patients With a History of Cancer in Clinical Studies of Brodalumab , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
K Gordon, K Papp, M Gooderman, D Thaci, P Foley, A Morita, S Kundu, R Kisa, A Napoli, S Banerjee, Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
A Armstrong, RG Langley, KB Gordon, RB Warren, D Thaçi, L Stein Gold, L Peterson, C Madden, N Nunez Gomez, D de Cuyper, A Costanzo, Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

<< < 1 2 3 4

Main Article Content

Keywords

Abstract

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)